J8P Stock Overview
A clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Cinclus Pharma Holding AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 2.80 |
52 Week High | SEK 3.04 |
52 Week Low | SEK 2.62 |
Beta | 0 |
11 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -2.35% |
Recent News & Updates
Recent updates
Shareholder Returns
J8P | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -4.8% | -2.8% | -2.7% |
1Y | n/a | -23.3% | 0.7% |
Return vs Industry: Insufficient data to determine how J8P performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how J8P performed against the German Market.
Price Volatility
J8P volatility | |
---|---|
J8P Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 4.7% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: J8P has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine J8P's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 13 | Christer Ahlberg | www.cincluspharma.com |
Cinclus Pharma Holding AB (publ), a clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases. Its lead product is linaprazan glurate for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer bacteria Helicobacter pylori (H. pylori). The company was founded in 2014 and is based in Stockholm, Sweden.
Cinclus Pharma Holding AB (publ) Fundamentals Summary
J8P fundamental statistics | |
---|---|
Market cap | €131.36m |
Earnings (TTM) | -€17.45m |
Revenue (TTM) | €254.04k |
517.1x
P/S Ratio-7.5x
P/E RatioIs J8P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
J8P income statement (TTM) | |
---|---|
Revenue | SEK 2.95m |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 2.95m |
Other Expenses | SEK 205.78m |
Earnings | -SEK 202.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.36 |
Gross Margin | 100.00% |
Net Profit Margin | -6,870.90% |
Debt/Equity Ratio | -128.7% |
How did J8P perform over the long term?
See historical performance and comparison